Nathaniel Baker to Marijuana Abuse
This is a "connection" page, showing publications Nathaniel Baker has written about Marijuana Abuse.
Connection Strength
2.854
-
Biological correlates of self-reported new and continued abstinence in cannabis cessation treatment clinical trials. Drug Alcohol Depend. 2018 06 01; 187:270-277.
Score: 0.480
-
Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial. Drug Alcohol Depend. 2021 12 01; 229(Pt B):109111.
Score: 0.152
-
Latency to cannabis dependence mediates the relationship between age at cannabis use initiation and cannabis use outcomes during treatment in men but not women. Drug Alcohol Depend. 2021 01 01; 218:108383.
Score: 0.143
-
Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder. Psychopharmacology (Berl). 2020 Feb; 237(2):479-490.
Score: 0.134
-
Tobacco use during cannabis cessation: Use patterns and impact on abstinence in a National Drug Abuse Treatment Clinical Trials Network study. Drug Alcohol Depend. 2018 11 01; 192:59-66.
Score: 0.123
-
The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial. Drug Alcohol Depend. 2018 04 01; 185:17-22.
Score: 0.118
-
Approach bias modification for cannabis use disorder: A proof-of-principle study. J Subst Abuse Treat. 2018 04; 87:16-22.
Score: 0.118
-
Incremental validity of estimated cannabis grams as a predictor of problems and cannabinoid biomarkers: Evidence from a clinical trial. Drug Alcohol Depend. 2018 01 01; 182:1-7.
Score: 0.116
-
Repetitive transcranial magnetic stimulation (rTMS) administration to heavy cannabis users. Am J Drug Alcohol Abuse. 2018; 44(1):47-55.
Score: 0.115
-
A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend. 2017 08 01; 177:249-257.
Score: 0.113
-
Gender differences among treatment-seeking adults with cannabis use disorder: Clinical profiles of women and men enrolled in the achieving cannabis cessation-evaluating N-acetylcysteine treatment (ACCENT) study. Am J Addict. 2017 Mar; 26(2):136-144.
Score: 0.110
-
Effect of oxytocin pretreatment on cannabis outcomes in a brief motivational intervention. Psychiatry Res. 2017 Mar; 249:318-320.
Score: 0.110
-
Alcohol use during a trial of N-acetylcysteine for adolescent marijuana cessation. Addict Behav. 2016 12; 63:172-7.
Score: 0.107
-
Gender differences in cannabis use disorder treatment: Change readiness and taking steps predict worse cannabis outcomes for women. Addict Behav. 2016 09; 60:197-202.
Score: 0.105
-
Vilazodone for cannabis dependence: A randomized, controlled pilot trial. Am J Addict. 2016 Jan; 25(1):69-75.
Score: 0.102
-
Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial. Drug Alcohol Depend. 2015 Nov 01; 156:29-37.
Score: 0.100
-
Concordance of Direct and Indirect Measures of Medication Adherence in A Treatment Trial for Cannabis Dependence. J Subst Abuse Treat. 2015 Oct; 57:70-4.
Score: 0.098
-
Cognitive performance in a placebo-controlled pharmacotherapy trial for youth with marijuana dependence. Addict Behav. 2015 Jun; 45:119-23.
Score: 0.096
-
Cigarette smoking during an N-acetylcysteine-assisted cannabis cessation trial in adolescents. Am J Drug Alcohol Abuse. 2014 Jul; 40(4):285-91.
Score: 0.091
-
Effect of oxytocin on craving and stress response in marijuana-dependent individuals: a pilot study. Psychopharmacology (Berl). 2013 Aug; 228(4):623-31.
Score: 0.085
-
Marijuana craving trajectories in an adolescent marijuana cessation pharmacotherapy trial. Addict Behav. 2013 Mar; 38(3):1788-91.
Score: 0.082
-
A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry. 2012 Aug; 169(8):805-12.
Score: 0.081
-
Stress- and cue-elicited craving and reactivity in marijuana-dependent individuals. Psychopharmacology (Berl). 2011 Nov; 218(1):49-58.
Score: 0.075